Results 71 to 80 of about 2,795 (144)

Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19. [PDF]

Pulm Ther
Merlo CA, Romdhani H, DerSarkissian M, Muthukumar A, McGarry LJ, Lou Y, Van Brunt K.   +6 more
europepmc   +1 more source

Effect of elexacaftor-tezacaftor-ivacaftor therapy on systemic inflammation in people with cystic fibrosis. [PDF]

J Bras Pneumol
Meyer VMC, Aranha Netto N, Palmeira P, Athanazio RA, Silva-Filho LVRFD.   +4 more
europepmc   +1 more source

Decreased pulmonary exacerbations and lower intravenous antibiotic usage following vanzacaftor/tezacaftor/deutivacaftor treatment in people with cystic fibrosis with <i>F508del</i>-minimal function genotypes. [PDF]

Eur Respir J
Horsley A, Arteaga-Solis E, Keating C, Mall MA, Ramsey B, Nair N, Thorat T, Sosnay P.   +7 more
europepmc   +1 more source

Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry. [PDF]

ERJ Open Res
Stahl M, Gerts FS, Hafkemeyer S, Wosniok J, Naehrlich L, German CF Registry of the Mukoviszidose e.V. and participating sites.   +5 more
europepmc   +1 more source

12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]

Genet Med Open
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc   +1 more source

Management of Infants Exposed to Prenatal and Postnatal Elexacaftor/Tezacaftor/Ivacaftor: A Cross-Sectional Survey. [PDF]

Health Sci Rep
Haskett H, Ren CL.
europepmc   +1 more source

Predictive capacity of paediatric nasal epithelial cells in sequential CFTR modulator therapy. [PDF]

Thorax
Fawcett LK, Chew ZA, Schneider-Futschik EK, Allan KM, Patel HR, Jaffe A, Waters S.   +6 more
europepmc   +1 more source

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]

J Clin Med
Boni A, Vassallo C, Ciciriello F, Cristiani L, Mancini A, Zucaro L, Graziano S, Goffredo BM, Alghisi F, Raponi M, Fabietti I, On Behalf Of Opbg Cf Pregnancy And Fetal Therapy Multidisciplinary Group.   +11 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Elexacaftor, Tezacaftor, and Ivacaftor

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source